PT  - JOURNAL ARTICLE
AU  - Balayla, Jacques
AU  - Lasry, Ariane
AU  - Gil, Yaron
AU  - Volodarsky-Perel, Alexander
TI  - Prevalence Threshold and Temporal Interpretation of Screening Tests: The Example of the SARS-CoV-2 (COVID-19) Pandemic
AID  - 10.1101/2020.05.17.20104927
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.17.20104927
4099  - http://medrxiv.org/content/early/2020/05/22/2020.05.17.20104927.short
4100  - http://medrxiv.org/content/early/2020/05/22/2020.05.17.20104927.full
AB  - The curvilinear relationship between a screening test’s positive predictive value (PPV) and its target disease prevalence is proportional. In consequence, there is an inflection point of maximum curvature in the screening curve defined as a function of the sensitivity (a) and specificity (b) beyond which the rate of change of a test’s PPV declines sharply relative to disease prevalence (ϕ). Herein, we demonstrate a mathematical model exploring this phenomenon and define the prevalence threshold point (ϕe) where this change occurs as: Understanding where this prevalence point lies in the curve has important implications for the interpretation of test results, the administration of healthcare systems, the implementation of public health measures, and in cases of pandemics like SARS-CoV-2, the functioning of society at large. To illustrate the methods herein described, we provide the example of the screening strategies used in the SARS-CoV-2 (COVID-19) pandemic, and calculate the prevalence threshold statistic of different tests available today. This concept can help contextualize the validity of a screening test in real time, thereby enhancing our understanding of the dynamics of the current pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe received no external funding for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used publicly available estimates for sensitivities and specificities of different COVID-19 tests, as published by the Center for Health Security at John Hopkins University. https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html